Source:http://linkedlifedata.com/resource/umls/id/C1510480
PDQ: A synthetic benzamide derivative. MS-275 binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. MS-275 appears to exert dose-dependent effects in human leukemia cells including p21(CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. p21(CIP1/WAF1) is an inhibitor of cyclin-dependent kinases; in normal cells, its expression has been associated with cell-cycle exit and differentiation. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38294&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=38294&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2724" NCI Thesaurus)